Featured Research

from universities, journals, and other organizations

Fears Of Gene-Therapy Dna Passed To Next Generation Statistically Unfounded: Penn Geneticist's Estimates Affect FDA Gene-Therapy Policy

Date:
June 2, 1999
Source:
University Of Pennsylvania Medical Center
Summary:
Ever since gene therapy was introduced almost ten years ago, there's been much apprehension about genes from the disabled viruses used in the therapies inserting their own genetic material into a recipient's reproductive cells. The fear is that viral DNA could reach sperm or egg cells and potentially the genome of subsequent generations.

Ever since gene therapy was introduced almost ten years ago, there's been much apprehension about genes from the disabled viruses used in the therapies inserting their own genetic material into a recipient's reproductive cells. The fear is that viral DNA could reach sperm or egg cells and potentially the genome of subsequent generations. Deciding on an acceptable level of this potential insertion has remained a contentious issue in setting policies for gene-therapy trials. The Federal Drug Administration (FDA) has proposed that a desirable limit would be no more than 1 insertion in about every 6,000 sperm cells, or individuals.

To help put this level into context, Haig Kazazian, MD, professor of genetics at the University of Pennsylvania School of Medicine estimated the natural incidence of gene insertions. He found that naturally occurring insertions in sperm cells were 100 times more common than the suggested FDA limit. His report is published in the June issue of Nature Genetics.

"There's a lot of concern about insertions of viral or other DNA from exogenous somatic gene therapy into gametes that could be passed on to the next generation," says Kazazian. "The FDA has been concerned about allowing studies where there was a chance of this." Kazazian's estimates -- along with other considerations -- were sufficiently convincing that the FDA no longer absolutely requires investigators to analyze gametic insertion before approving gene-therapy studies.

The major cause of naturally occurring genomic insertions is retrotransposons, so-called jumping genes. These are sequences of genetic material that are capable of duplicating and randomly reinserting themselves into the genome. Protein-coding sequences of retrotransposons are quite similar to some bacterial sequences, so are thought to be very old and therefore also important from an evolutionary standpoint.

Based on data found in the scientific literature and the Human Gene Mutation Database, Kazazian estimated that roughly 1 in 600 mutations arise from retrotransposon-mediated insertions and that there are on average 75 mutations derived from sperm cells in an individual. This means that 1 individual in every 8 (75 times 1/600) will carry a new retrotransposon insertion.

"Even if we overestimate this number by a factor of ten and say that one naturally occurring insertion is expected in every 50 to 100 individuals, this is still far greater than the one insertion in 6,000 sperm cells that has been suggested by the FDA," notes Kazazian. In addition, researchers consider most insertions harmless because critical sequences of DNA are thought to make up less than 5 percent of the human genome.


Story Source:

The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pennsylvania Medical Center. "Fears Of Gene-Therapy Dna Passed To Next Generation Statistically Unfounded: Penn Geneticist's Estimates Affect FDA Gene-Therapy Policy." ScienceDaily. ScienceDaily, 2 June 1999. <www.sciencedaily.com/releases/1999/06/990602072305.htm>.
University Of Pennsylvania Medical Center. (1999, June 2). Fears Of Gene-Therapy Dna Passed To Next Generation Statistically Unfounded: Penn Geneticist's Estimates Affect FDA Gene-Therapy Policy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/06/990602072305.htm
University Of Pennsylvania Medical Center. "Fears Of Gene-Therapy Dna Passed To Next Generation Statistically Unfounded: Penn Geneticist's Estimates Affect FDA Gene-Therapy Policy." ScienceDaily. www.sciencedaily.com/releases/1999/06/990602072305.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins